Navigation Links
Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial
Date:3/6/2008

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, March 6 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has started its first EDACS(TM) product Phase I clinical trial. EDACS(TM) is Akela's patent pending platform technology to prevent abuse of controlled substances.

This Phase I trial for the first EDACS(TM) based product is an open-label, randomized, single-dose, cross-over study investigating the pharmacokinetics and safety of 3 different extended release formulations of a well-known opioid product compared to the same opioid drug immediate release formulation. The study will be carried out in 12 healthy subjects, and the results are expected to be available in Q3/2008.

"The abuse of prescription drugs is approaching epidemic proportions in numerous countries. The costs to society associated with this abuse are tremendous. Akela has developed a platform technology to prevent the abuse of such substances by preventing the tampering of extended release dosage forms as well as unintentional dose dumping in alcohol. " said Dr. Halvor Jaeger, Chief Executive Officer of Akela Pharma Inc. "We believe that our platform technology is perfectly suited to meet the increasing market demand as well as regulatory pressure for abuse deterrent formulations."

About EDACS(TM):

EDACS(TM) is a patent pending platform technology which utilizes extrusion technology to prepare an insoluble matrix containing dispersed drug which can be shaped into tablets. The matrix is water insoluble, slightly soluble in ethanol, not friable, does not break on compression or allow for crushing and inhalation and does not allow for dissolution and injection.

About Akela Pharma Inc.:

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of Akela Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE Akela Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
2. Akela Pharma provides corporate update
3. Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
4. Akela Pharma reports results for third quarter of fiscal 2007
5. AKELA Pharma Inc. announces U.S. public offering and proposed listing
6. Akela Pharma Inc. Completes Share Consolidation
7. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
8. MinuteClinic Hits 500th Clinic Mark; New Locations Open in Dallas, Los Angeles and Orlando CVS/pharmacy Stores
9. Notice of Bradmer Pharmaceuticals Conference Call
10. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
11. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: